Wetenschappelijke publicaties
COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study
Hoeve CE (Conformité Européenne), Huiberts AJ, de Gier B, Andeweg SP (Sustainable Procurement), den Hartog G, de Melker HE, et al.
Vaccine. 2024; S0264-410X(24)00783-7
Health-related quality of life during the COVID-19 pandemic: The impact of restrictive measures using data from two Dutch population-based cohort studies
van Hagen CCE (Coordination Centre for Effects), Huiberts AJ, Mutubuki EN, de Melker HE, Vos ERA, van de Wijgert JHHM, et al.
PlosONE. 2024;19(3)
Association between adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations, the Netherlands, May 2021 to November 2022: a population-based prospective cohort study
Holwerda MR (antimicrobial resistance), Hoeve CE, Huiberts AJ, den Hartog G, de Melker HE, van den Hof S, Knol MJ
Euro Surveill. 2024;29(25)
Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024 Huiberts AJ, Hoeve CE, de Gier B, Cremer J, van der Veer B, de Melker HE, et al.
Eurosurveillance 2024;29(10)
Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study
Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahne SJM, den Hartog G, et al.
International Journal of Infectious Disease. 2023;133:36-42
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahne SJ, den Hartog G, et al.
Eurosurveillance. 2023;28(7)
Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology
de Gier B, Huiberts AJ, Hoeve CE, den Hartog G, van Werkhoven H, van Binnendijk R, et al.
Nature communications 2023;14(1):4793
Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022
Hoeve CE, de Gier B, Huiberts AJ, de Melker HE, Hahne SJM, van den Hof S, Knol MJ
Journal of Infectious Diseases 2023;228(4):431-8
Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein
den Hartog G, Andeweg SP, Hoeve CE, Smits G, Voordouw B, Eggink D, et al.
Scientific reports. 2023;13(1):18394
Design and baseline description of an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands - The VAccine Study COvid-19 (VASCO)
Huiberts AJ, Kooijman MN, de Melker HE, Hahne SJ, Grobbee DE, Hoeve CE, et al.
ResearchSquare. 2022 (preprint)
Rapportages
COVID-19-vaccinatie. Achtergrondinformatie voor de Gezondheidsraad.
Centrum Infectieziektebestrijding
Bilthoven, Rijksinstituut voor Volksgezondheid en Milieu, 2024. RIVM rapport 2024-055
The National Immunisation Programme in the Netherlands – Surveillance and developments in 2022-2023.(PDF)
Pluijmaekers AJM, de Melker HE, et al.
Bilthoven, Rijksinstituut voor Volksgezondheid en Milieu, 2023. RIVM rapport 2023-0330
Hoofdstuk 9
The National Immunisation Programme in the Netherlands – Surveillance and developments in 2021-2022.(PDF)
Pluijmaekers AJM, de Melker HE, et al.
Bilthoven, Rijksinstituut voor Volksgezondheid en Milieu, 2022. RIVM rapport 2021-0042
Hoofdstuk 9
The National Immunisation Programme in the Netherlands – Surveillance and developments in 2020-2021.(PDF)
Pluijmaekers AJM, de Melker HE, et al.
Bilthoven, Rijksinstituut voor Volksgezondheid en Milieu, 2021. RIVM rapport 2021-0055
Hoofdstuk 9